When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection they are able to communicate what is unique about their offering to the right audience at the right time.
While some are waiting for mandates for traceability, serialization, and aggregation, others are recognizing the inevitability of these strategies. Does your CMO have a dedicated traceability operation in place?
Highly potent active pharmaceutical ingredients (HPAPIs) represent an increasing fraction of new compounds in pharmaceutical pipelines today. Flexible and phase-appropriate infrastructure is needed to bring the next innovative medicines based on these challenging compounds from concept to commercialization. Thispresentation describes Lonza's HPAPI "manufacturing 4.0" investments and the company's innovative capabilities.